Parkworth Wealth Management’s Cytokinetics CYTK Stock Holding History

Parkworth Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$264	Buy	+8	New	+$278	﹤0.01%	847

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Parkworth Wealth Management's CYTK Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Cytokinetics (CYTK) in Q2 2025: 8 shares worth $264. The stake represents ﹤0.01% of the portfolio and ranks #847 among its holdings.

311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Parkworth Wealth Management held 8 shares of Cytokinetics worth $264 as of Q2 2025.
Cytokinetics was a new Parkworth Wealth Management position in Q2 2025.
Cytokinetics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #847 holding.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.